NZ631789A - Combination of direct acting antiviral agents and ribavirin for treating hcv patients - Google Patents
Combination of direct acting antiviral agents and ribavirin for treating hcv patientsInfo
- Publication number
- NZ631789A NZ631789A NZ631789A NZ63178914A NZ631789A NZ 631789 A NZ631789 A NZ 631789A NZ 631789 A NZ631789 A NZ 631789A NZ 63178914 A NZ63178914 A NZ 63178914A NZ 631789 A NZ631789 A NZ 631789A
- Authority
- NZ
- New Zealand
- Prior art keywords
- ribavirin
- antiviral agents
- direct acting
- combination
- acting antiviral
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed is the use of at least two direct acting antiviral agents (DAAs) and ribavirin for the manufacture of a medicament for the treatment of Hepatitis C virus (HCV) in an HCV patient, wherein said treatment does not include interferon, and wherein said at least two DAAs comprise: Compound 1 (glecaprevir) or a pharmaceutically acceptable salt thereof, and Compound 2 (Pibrentasvir) or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461783437P | 2014-03-14 | 2014-03-14 | |
PCT/US2014/027556 WO2014152635A1 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ631789A true NZ631789A (en) | 2018-01-26 |
Family
ID=61012481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ631789A NZ631789A (en) | 2014-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ631789A (en) |
-
2014
- 2014-03-14 NZ NZ631789A patent/NZ631789A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
MX2016012799A (en) | Methods for treating hcv. | |
MX2015012536A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients. | |
PH12014502847A1 (en) | Combination treatment (eg with abt-072-333) of daas for use in treating hcv | |
MX2018005230A (en) | Combination therapy of an hbv capsid assembly inhibitor and an interferon. | |
MX2017011488A (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor. | |
PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
JP2016513703A5 (en) | ||
MX2018000240A (en) | Methods for treating hcv. | |
MX2021014771A (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor. | |
RU2015114543A (en) | HEPATITIS TREATMENT METHODS | |
MX2021010145A (en) | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases. | |
MX2016012722A (en) | Methods for treating hcv. | |
WO2016014527A3 (en) | Stabilized nucleotides for medical treatment | |
PH12018502735A1 (en) | Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof | |
PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
RU2015114566A (en) | HEPATITIS TREATMENT METHODS | |
NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
MX2020001422A (en) | Methods for treating hcv. | |
MX2018001905A (en) | Methods for treating hcv. | |
WO2014122537A3 (en) | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin | |
MX2018000213A (en) | Methods for treating hcv. | |
AU2019384793A8 (en) | Methods for treating acute HCV | |
EA201491652A1 (en) | MEANS FOR TREATING VIRAL HEPATITIS C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 MAR 2021 BY SPRUSON + FERGUSON Effective date: 20180531 |
|
S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
LAPS | Patent lapsed |